Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $196.80, for a total transaction of $393,600.00. Following the completion of the transaction, the executive vice president now owns 37,941 shares in the company, valued at approximately $7,466,788.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Marc Stapley also recently made the following trade(s):

  • On Friday, July 14th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $173.56, for a total transaction of $347,120.00.
  • On Monday, June 12th, Marc Stapley sold 2,000 shares of Illumina stock. The stock was sold at an average price of $170.85, for a total transaction of $341,700.00.

Shares of Illumina, Inc. (NASDAQ ILMN) traded up 2.63% during mid-day trading on Monday, reaching $199.58. 938,509 shares of the company’s stock were exchanged. The stock has a market cap of $29.14 billion, a price-to-earnings ratio of 40.04 and a beta of 0.83. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95. The stock’s 50-day moving average is $174.66 and its 200-day moving average is $171.89.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the previous year, the business posted $0.86 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities analysts expect that Illumina, Inc. will post $3.65 EPS for the current year.

WARNING: “Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley Sells 2,000 Shares” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/07/illumina-inc-nasdaqilmn-evp-marc-stapley-sells-2000-shares-2.html.

A number of institutional investors have recently added to or reduced their stakes in ILMN. Jennison Associates LLC boosted its position in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares during the period. American Century Companies Inc. boosted its position in Illumina by 276.9% in the second quarter. American Century Companies Inc. now owns 475,111 shares of the life sciences company’s stock worth $82,441,000 after buying an additional 349,058 shares during the period. Vanguard Group Inc. boosted its position in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after buying an additional 285,379 shares during the period. TIAA CREF Investment Management LLC boosted its position in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock worth $161,787,000 after buying an additional 271,461 shares during the period. Finally, Baird Financial Group Inc. boosted its position in Illumina by 1,110.5% in the first quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock worth $47,629,000 after buying an additional 256,061 shares during the period. 93.81% of the stock is owned by hedge funds and other institutional investors.

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating and set a $202.18 target price for the company. in a research report on Wednesday, August 2nd. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and boosted their target price for the stock from $170.00 to $215.00 in a research report on Monday. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $175.00 target price (up from $165.00) on shares of Illumina in a research report on Saturday, April 29th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $176.63.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.